Cover Image
Market Research Report
Product code 
1092806

Global Cancer Gene Therapy Market Size, Share & Industry Trends Analysis Report By Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer), By End User, By Regional Outlook and Forecast, 2022 - 2028

Published: | KBV Research | 153 Pages | Delivery time: 1-2 business days

Price

Back to Top
Global Cancer Gene Therapy Market Size, Share & Industry Trends Analysis Report By Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer), By End User, By Regional Outlook and Forecast, 2022 - 2028
Published: April 29, 2022
KBV Research
Content info: 153 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The Global Cancer Gene Therapy Market size is expected to reach $5 billion by 2028, rising at a market growth of 21.2% CAGR during the forecast period.

Gene therapy is the process of replacing faulty or damaged genes at the molecular level. It is a procedure in which viruses are genetically modified before being transmitted to host cells. Viruses are genetically modified to contain a gene that is now frequently used to cure cancer. The pipeline for cancer gene therapy is quite strong, and various industry participants have recently concentrated their efforts on developing a number of successful cancer gene therapies and vectors. Pre-marketing approval is required for the marketing of cancer gene therapy, and it is a lengthy process that is closely reviewed. As a result, there are few cancer gene treatments on the market, and they are still in development. However, vectors, which are essential for gene transfer and are pre-requisites for gene therapy, are increasingly being used in study and treatment.

Cancer is described as uncontrolled cell development in the body that results in organ failure. It can be fatal if left untreated. The body manages uncontrolled cell proliferation in numerous ways, one of which is by deploying white blood cells to detect and kill malignant cells. The immune system has been discovered to be influenced in order to cause malignant cells to self-destruct. The effects of radiation and chemotherapy therapy on malignant cells in the body are constant and dependable. Immunotherapy for hematological tumors has recently gained popularity and is attracting the attention of numerous researchers. Scientists have devised a method for isolating, replicating, and developing cancer-destroying cells from a patient's blood cancer and then injecting those cells back into the patient to eliminate their tumors, resulting in long-term remissions.

Cancer has a strong tendency to spread throughout the body. It is the world's second-leading cause of death. Cancer gene therapy is a strategy for treating cancer that involves inserting therapeutic DNA into the patient's gene. Cancer gene therapy has grown in popularity as a result of its high success rate in preclinical and clinical trials. A treatment in which the mutant gene is replaced with a healthy gene or the deactivation of a gene whose function is improper are examples of cancer gene therapy procedures. A new strategy for combating cancer cells has just been devised, in which new genes are delivered into the body.

COVID-19 Impact

The COVID-19 pandemic has hampered the market for cancer gene therapy. Doctors from Dana Farber Cancer Institute discovered that during the COVID-19 pandemic, there was a 46 percent decline in diagnoses of the six most frequent cancer types - breast, pancreatic, colorectal, lung, gastric, and oesophageal cancers, according to research published in Cancer Connect 2020. Furthermore, the Centres for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health-prevention services, as well as elective surgeries, be postponed unless the risks outweighed the benefits, in order to secure hospital infrastructure for COVID-19 patients' treatment. As a result, the COVID-19 pandemic has had an influence on the market for cancer gene therapy.

Market Growth Factors

Growing cases of Cancer

In recent years, there has been a rising burden of cancer disease, the expanding focus on research to create an effective cancer treatment, and growing investments in cancer research. According to Globocan 2020, an expected 19,292,789 new cancer cases and 9,958,133 cancer-related deaths were reported worldwide in 2020. Various gene therapy strategies are now being used in the treatment of cancer. Anti-angiogenic gene therapy, pro-drug activating suicide gene therapy, gene therapy-based immune modulation, oncolytic virotherapy, gene correction/compensation, antisense, genetic manipulation of apoptotic and tumor invasion pathways, and RNAi techniques are only a few examples. These medicines have been used to treat cancers such as brain, lung, breast, pancreas, liver, prostate, colorectal, bladder, head & neck, skin, ovarian, and renal cancer.

Supportive regulations

An improving regulatory landscape would help the industry players to optimize the opportunities. In addition, manufacturers are subject to regulations to secure the admission of defect-free products (vectors) onto the market, as they are associated with people's health. Because any flaws in gene therapy goods could be lethal to patients, laws have been changed to ensure that no products are recalled during post-market surveillance. Better success rates of novel medicines, ethical acceptance of gene therapy for cancer treatment, and enormous unexplored markets in emerging nations are expected to impact the market in the long run.

Market Restraining Factors

High cost of Cancer Gene Therapy

Gene therapy can be very expensive, thereby discouraging many people from choosing this mode of treatment. In the United States, for example, Zolgensma, gene therapy for spinal muscular atrophy, is the most expensive drug. In many countries, people have low disposable income, so spending high costs on healthcare is still a distant dream for them. Moreover, many governments are reeling from the negative impacts brought by the COVID-19 pandemic on their economy and healthcare infrastructure. The high expense of cancer gene therapy is due to the need for extensive clinical studies; also, unlike other pharmaceuticals, treatment by cancer gene therapy varies from person to person depending on the genetic acceptance of each patient.

Therapy Outlook

Based on Therapy, the market is segmented into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. In 2021, the Gene Transfer segment held a promising revenue share of the Cancer Gene Therapy Market. Gene transfer is a new treatment method that involves introducing new modified genes into malignant cells or associated tissue in order to kill the cells or restrict their growth. This method is adaptable, as it may be employed with a wide range of vectors and genes in clinical trials with positive results. Gene therapy could be utilized alone or in combination with other treatments to control the condition as technology advances. Naked/plasmid vectors, electroporation, sonoporation, magnetoreception, and gene gun are all used to transfer or replace genes.

End User Outlook

Based on End User, the market is segmented into Hospitals, Diagnostic centers and Research Institutes. In 2021, the hospital segment collected the maximum revenue share of the Cancer Gene Therapy Market. This is owing to rising healthcare awareness, an increase in the number of hospitals, and an increase in the geriatric and bariatric populations. Therefore, these factors would continue to boost the growth of the segment even during the forecasting period.

Regions Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2021, the North America emerged as the leading region in the overall Cancer Gene Therapy Market by procuring the highest revenue share of the market. The growth of the regional market is owing to the huge investments in research and technological breakthroughs. The region's viral vectors and plasmid DNA market is boosted by the presence of a huge population base, government measures to develop healthcare facilities, and a rise in healthcare expenditure.

Strategies Deployed in Cancer Gene Therapy Market

Apr-2022: Kite, a Gilead Company received approval from U.S. Food and Drug Administration (FDA) for Yescarta CAR T-cell therapy. This approval focused on adult patients with huge B-cell lymphoma that is disobedient to first-line chemoimmunotherapy or that worsen within 12 months of starting chemoimmunotherapy.

Mar-2022: Novartis signed an agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics. This agreement aimed to launch HER 2 targeted CAR-M cell therapy, which is certified in basic tests for the therapy of solid tumors. Additionally, The Global Biotech Cooperations unit of Novartis is completed engaged to collaborate with Carisma Therapeutics to carry CAR-M cell treatments to patients by providing its proven state-of-the-art cell and gene manufacturing abilities.

Dec-2021: Novartis signed an agreement to acquire Gyroscope Therapeutics, a clinical-stage gene therapy company. Through this acquisition, Novartis would achieve access to the prior guide experimental gene treatment, GT005.

Dec-2021: Novartis unveiled T-Charge, the organization's next-generation CAR-T platform. The platform would offer a base for diverse new investigational CAR-T cell treatments in the Novartis pipeline. Additionally, the T-Charge platform conserves T cell stemness, the capabilities to mature and renew, which results in a product embracing greater proliferative potential and lesser exhausted T cells. Moreover, T-Charge, CAR-T cell growth occurs mainly within a patient's body, reducing the need for an extended culture time outside of the body. Furthermore, the unique attribute of the T-Charge platform may guide to superior and more strong responses, enhance long-term conclusion and a minimize danger of harsh adverse events.

Mar-2021: Novartis received an approval from Health Sciences Authority for Kymriah as the first economic chimeric antigen receptor T-cell therapy. Additionally, Kymriah, a CD19-directed constitutionally customized autologous T-cell immunocellular therapy, is accepted to treat two fatal cancers that have restricted treatment choices and historically worst conclusions, addressing the crucial demand for new treatments for patients.

Mar-2021: Bristol Myers Squibb along with bluebird bio received a U.S. Food and Drug Administration has approved Abecma, as the first B-cell maturation antigen directed chimeric antigen receptor T cell immunotherapy. The approval offers medication for adult patients with refractory or relapsed various myeloma after four or more preceding lines of therapy, such as a proteasome inhibitor, an anti-CD38 monoclonal antibody, and an immunomodulatory agent. Additionally, Abecma is a customized immune cell therapy accepted as a one-time mixture with an approved dose range of 300 to 460 x 106 CAR-positive T cells.

Jan-2020: Adapta Immue signed a co-development and co-commercialization agreement with Astellas Pharma, a Japanese multinational pharmaceutical company. Through this agreement, the companies aimed to launch new stem-cell concluded allogeneic T-cell therapies for patients with cancer. Additionally, the collaboration would use Adaptimmune's target recognition and affirmation abilities for creating target-specific chimeric antigen receptors, HLA-independent TCRs, and T-cell Receptors that identify surface epitopes freely of the HLA overview of the tumor cell.

Oct-2019: GlaxoSmithKline joined hands with Lyell Immunopharma, operator of a biotechnology company. Through this collaboration, the companies aimed to enhance cell therapies for cancer patients. Additionally, the collaboration would approach Lyell's technologies to further reinforce GSK's cell treatment pipeline, such as GSK3377794, which marks the NY-ESO-1 antigen that is announced around various cancer types.

Mar-2019: Bristol-Myers Squibb merged with Celgene, a pharmaceutical company that makes cancer and immunology drugs. Through this merger, Bristol-Myers Squibb would acquire Celgene to build a dominant concentrated specialty biopharma enterprise well positioned to meet the demands of patients with cancer, immunologic, inflammatory disease, and cardiovascular disease through great value creative medicines and dominating scientific abilities. Additionally, the integrated enterprise would provide global scale and reach, preserving the agility and speed that is core to each enterprise's strategic access.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, GlaxoSmithKline PLC (GSK), Amgen, Inc., Bristol Myers, Squibb Company, Karyopharm Therapeutics, Inc., Gilead Sciences, Inc., Adaptimmune Limited, Genelux Corporation, and Sarepta Therapeutics, Inc

Scope of the Study

Market Segments covered in the Report:

By Therapy

  • Gene Induced Immunotherapy
  • Oncolytic Virotherapy, and
  • Gene Transfer

By End User

  • Hospitals
  • Diagnostic centers
  • Research Institutes

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Novartis AG
  • GlaxoSmithKline PLC (GSK)
  • Amgen, Inc.
  • Bristol Myers Squibb Company
  • Karyopharm Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Adaptimmune Limited
  • Genelux Corporation
  • Sarepta Therapeutics, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Cancer Gene Therapy Market, by Therapy
    • 1.4.2 Global Cancer Gene Therapy Market, by End User
    • 1.4.3 Global Cancer Gene Therapy Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Cancer Gene Therapy Market by Therapy

  • 3.1 Global Gene Induced Immunotherapy Market by Region
  • 3.2 Global Oncolytic Virotherapy Market by Region
  • 3.3 Global Gene Transfer Market by Region

Chapter 4. Global Cancer Gene Therapy Market by End User

  • 4.1 Global Hospitals Market by Region
  • 4.2 Global Diagnostic centers Market by Region
  • 4.3 Global Research Institutes Market by Region

Chapter 5. Global Cancer Gene Therapy Market by Region

  • 5.1 North America Cancer Gene Therapy Market
    • 5.1.1 North America Cancer Gene Therapy Market by Therapy
      • 5.1.1.1 North America Gene Induced Immunotherapy Market by Country
      • 5.1.1.2 North America Oncolytic Virotherapy Market by Country
      • 5.1.1.3 North America Gene Transfer Market by Country
    • 5.1.2 North America Cancer Gene Therapy Market by End User
      • 5.1.2.1 North America Hospitals Market by Country
      • 5.1.2.2 North America Diagnostic centers Market by Country
      • 5.1.2.3 North America Research Institutes Market by Country
    • 5.1.3 North America Cancer Gene Therapy Market by Country
      • 5.1.3.1 US Cancer Gene Therapy Market
        • 5.1.3.1.1 US Cancer Gene Therapy Market by Therapy
        • 5.1.3.1.2 US Cancer Gene Therapy Market by End User
      • 5.1.3.2 Canada Cancer Gene Therapy Market
        • 5.1.3.2.1 Canada Cancer Gene Therapy Market by Therapy
        • 5.1.3.2.2 Canada Cancer Gene Therapy Market by End User
      • 5.1.3.3 Mexico Cancer Gene Therapy Market
        • 5.1.3.3.1 Mexico Cancer Gene Therapy Market by Therapy
        • 5.1.3.3.2 Mexico Cancer Gene Therapy Market by End User
      • 5.1.3.4 Rest of North America Cancer Gene Therapy Market
        • 5.1.3.4.1 Rest of North America Cancer Gene Therapy Market by Therapy
        • 5.1.3.4.2 Rest of North America Cancer Gene Therapy Market by End User
  • 5.2 Europe Cancer Gene Therapy Market
    • 5.2.1 Europe Cancer Gene Therapy Market by Therapy
      • 5.2.1.1 Europe Gene Induced Immunotherapy Market by Country
      • 5.2.1.2 Europe Oncolytic Virotherapy Market by Country
      • 5.2.1.3 Europe Gene Transfer Market by Country
    • 5.2.2 Europe Cancer Gene Therapy Market by End User
      • 5.2.2.1 Europe Hospitals Market by Country
      • 5.2.2.2 Europe Diagnostic centers Market by Country
      • 5.2.2.3 Europe Research Institutes Market by Country
    • 5.2.3 Europe Cancer Gene Therapy Market by Country
      • 5.2.3.1 Germany Cancer Gene Therapy Market
        • 5.2.3.1.1 Germany Cancer Gene Therapy Market by Therapy
        • 5.2.3.1.2 Germany Cancer Gene Therapy Market by End User
      • 5.2.3.2 UK Cancer Gene Therapy Market
        • 5.2.3.2.1 UK Cancer Gene Therapy Market by Therapy
        • 5.2.3.2.2 UK Cancer Gene Therapy Market by End User
      • 5.2.3.3 France Cancer Gene Therapy Market
        • 5.2.3.3.1 France Cancer Gene Therapy Market by Therapy
        • 5.2.3.3.2 France Cancer Gene Therapy Market by End User
      • 5.2.3.4 Russia Cancer Gene Therapy Market
        • 5.2.3.4.1 Russia Cancer Gene Therapy Market by Therapy
        • 5.2.3.4.2 Russia Cancer Gene Therapy Market by End User
      • 5.2.3.5 Spain Cancer Gene Therapy Market
        • 5.2.3.5.1 Spain Cancer Gene Therapy Market by Therapy
        • 5.2.3.5.2 Spain Cancer Gene Therapy Market by End User
      • 5.2.3.6 Italy Cancer Gene Therapy Market
        • 5.2.3.6.1 Italy Cancer Gene Therapy Market by Therapy
        • 5.2.3.6.2 Italy Cancer Gene Therapy Market by End User
      • 5.2.3.7 Rest of Europe Cancer Gene Therapy Market
        • 5.2.3.7.1 Rest of Europe Cancer Gene Therapy Market by Therapy
        • 5.2.3.7.2 Rest of Europe Cancer Gene Therapy Market by End User
  • 5.3 Asia Pacific Cancer Gene Therapy Market
    • 5.3.1 Asia Pacific Cancer Gene Therapy Market by Therapy
      • 5.3.1.1 Asia Pacific Gene Induced Immunotherapy Market by Country
      • 5.3.1.2 Asia Pacific Oncolytic Virotherapy Market by Country
      • 5.3.1.3 Asia Pacific Gene Transfer Market by Country
    • 5.3.2 Asia Pacific Cancer Gene Therapy Market by End User
      • 5.3.2.1 Asia Pacific Hospitals Market by Country
      • 5.3.2.2 Asia Pacific Diagnostic centers Market by Country
      • 5.3.2.3 Asia Pacific Research Institutes Market by Country
    • 5.3.3 Asia Pacific Cancer Gene Therapy Market by Country
      • 5.3.3.1 China Cancer Gene Therapy Market
        • 5.3.3.1.1 China Cancer Gene Therapy Market by Therapy
        • 5.3.3.1.2 China Cancer Gene Therapy Market by End User
      • 5.3.3.2 Japan Cancer Gene Therapy Market
        • 5.3.3.2.1 Japan Cancer Gene Therapy Market by Therapy
        • 5.3.3.2.2 Japan Cancer Gene Therapy Market by End User
      • 5.3.3.3 India Cancer Gene Therapy Market
        • 5.3.3.3.1 India Cancer Gene Therapy Market by Therapy
        • 5.3.3.3.2 India Cancer Gene Therapy Market by End User
      • 5.3.3.4 South Korea Cancer Gene Therapy Market
        • 5.3.3.4.1 South Korea Cancer Gene Therapy Market by Therapy
        • 5.3.3.4.2 South Korea Cancer Gene Therapy Market by End User
      • 5.3.3.5 Singapore Cancer Gene Therapy Market
        • 5.3.3.5.1 Singapore Cancer Gene Therapy Market by Therapy
        • 5.3.3.5.2 Singapore Cancer Gene Therapy Market by End User
      • 5.3.3.6 Malaysia Cancer Gene Therapy Market
        • 5.3.3.6.1 Malaysia Cancer Gene Therapy Market by Therapy
        • 5.3.3.6.2 Malaysia Cancer Gene Therapy Market by End User
      • 5.3.3.7 Rest of Asia Pacific Cancer Gene Therapy Market
        • 5.3.3.7.1 Rest of Asia Pacific Cancer Gene Therapy Market by Therapy
        • 5.3.3.7.2 Rest of Asia Pacific Cancer Gene Therapy Market by End User
  • 5.4 LAMEA Cancer Gene Therapy Market
    • 5.4.1 LAMEA Cancer Gene Therapy Market by Therapy
      • 5.4.1.1 LAMEA Gene Induced Immunotherapy Market by Country
      • 5.4.1.2 LAMEA Oncolytic Virotherapy Market by Country
      • 5.4.1.3 LAMEA Gene Transfer Market by Country
    • 5.4.2 LAMEA Cancer Gene Therapy Market by End User
      • 5.4.2.1 LAMEA Hospitals Market by Country
      • 5.4.2.2 LAMEA Diagnostic centers Market by Country
      • 5.4.2.3 LAMEA Research Institutes Market by Country
    • 5.4.3 LAMEA Cancer Gene Therapy Market by Country
      • 5.4.3.1 Brazil Cancer Gene Therapy Market
        • 5.4.3.1.1 Brazil Cancer Gene Therapy Market by Therapy
        • 5.4.3.1.2 Brazil Cancer Gene Therapy Market by End User
      • 5.4.3.2 Argentina Cancer Gene Therapy Market
        • 5.4.3.2.1 Argentina Cancer Gene Therapy Market by Therapy
        • 5.4.3.2.2 Argentina Cancer Gene Therapy Market by End User
      • 5.4.3.3 UAE Cancer Gene Therapy Market
        • 5.4.3.3.1 UAE Cancer Gene Therapy Market by Therapy
        • 5.4.3.3.2 UAE Cancer Gene Therapy Market by End User
      • 5.4.3.4 Saudi Arabia Cancer Gene Therapy Market
        • 5.4.3.4.1 Saudi Arabia Cancer Gene Therapy Market by Therapy
        • 5.4.3.4.2 Saudi Arabia Cancer Gene Therapy Market by End User
      • 5.4.3.5 South Africa Cancer Gene Therapy Market
        • 5.4.3.5.1 South Africa Cancer Gene Therapy Market by Therapy
        • 5.4.3.5.2 South Africa Cancer Gene Therapy Market by End User
      • 5.4.3.6 Nigeria Cancer Gene Therapy Market
        • 5.4.3.6.1 Nigeria Cancer Gene Therapy Market by Therapy
        • 5.4.3.6.2 Nigeria Cancer Gene Therapy Market by End User
      • 5.4.3.7 Rest of LAMEA Cancer Gene Therapy Market
        • 5.4.3.7.1 Rest of LAMEA Cancer Gene Therapy Market by Therapy
        • 5.4.3.7.2 Rest of LAMEA Cancer Gene Therapy Market by End User

Chapter 6. Company Profiles

  • 6.1 Novartis AG
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Segmental and Regional Analysis
    • 6.1.4 Research & Development Expense
  • 6.2 GlaxoSmithKline PLC (GSK)
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Segmental and Regional Analysis
    • 6.2.4 Research & Development Expense
  • 6.3 Amgen, Inc.
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Regional Analysis
    • 6.3.4 Research & Development Expenses
  • 6.4 Bristol Myers Squibb Company
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Regional Analysis
    • 6.4.4 Research & Development Expenses
  • 6.5 Karyopharm Therapeutics, Inc.
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Research & Development Expense
  • 6.6 Gilead Sciences, Inc.
    • 6.6.1 Company overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Research & Development Expenses
  • 6.7 Adaptimmune Limited
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Research & Development Expenses
  • 6.8 Genelux Corporation
    • 6.8.1 Company Overview
  • 6.9 Sarepta Therapeutics, Inc.
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Research & Development Expenses

LIST OF TABLES

  • TABLE 1 Global Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 2 Global Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 3 Global Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 4 Global Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 5 Global Gene Induced Immunotherapy Market by Region, 2018 - 2021, USD Million
  • TABLE 6 Global Gene Induced Immunotherapy Market by Region, 2022 - 2028, USD Million
  • TABLE 7 Global Oncolytic Virotherapy Market by Region, 2018 - 2021, USD Million
  • TABLE 8 Global Oncolytic Virotherapy Market by Region, 2022 - 2028, USD Million
  • TABLE 9 Global Gene Transfer Market by Region, 2018 - 2021, USD Million
  • TABLE 10 Global Gene Transfer Market by Region, 2022 - 2028, USD Million
  • TABLE 11 Global Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 12 Global Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 13 Global Hospitals Market by Region, 2018 - 2021, USD Million
  • TABLE 14 Global Hospitals Market by Region, 2022 - 2028, USD Million
  • TABLE 15 Global Diagnostic centers Market by Region, 2018 - 2021, USD Million
  • TABLE 16 Global Diagnostic centers Market by Region, 2022 - 2028, USD Million
  • TABLE 17 Global Research Institutes Market by Region, 2018 - 2021, USD Million
  • TABLE 18 Global Research Institutes Market by Region, 2022 - 2028, USD Million
  • TABLE 19 Global Cancer Gene Therapy Market by Region, 2018 - 2021, USD Million
  • TABLE 20 Global Cancer Gene Therapy Market by Region, 2022 - 2028, USD Million
  • TABLE 21 North America Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 22 North America Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 23 North America Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 24 North America Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 25 North America Gene Induced Immunotherapy Market by Country, 2018 - 2021, USD Million
  • TABLE 26 North America Gene Induced Immunotherapy Market by Country, 2022 - 2028, USD Million
  • TABLE 27 North America Oncolytic Virotherapy Market by Country, 2018 - 2021, USD Million
  • TABLE 28 North America Oncolytic Virotherapy Market by Country, 2022 - 2028, USD Million
  • TABLE 29 North America Gene Transfer Market by Country, 2018 - 2021, USD Million
  • TABLE 30 North America Gene Transfer Market by Country, 2022 - 2028, USD Million
  • TABLE 31 North America Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 32 North America Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 33 North America Hospitals Market by Country, 2018 - 2021, USD Million
  • TABLE 34 North America Hospitals Market by Country, 2022 - 2028, USD Million
  • TABLE 35 North America Diagnostic centers Market by Country, 2018 - 2021, USD Million
  • TABLE 36 North America Diagnostic centers Market by Country, 2022 - 2028, USD Million
  • TABLE 37 North America Research Institutes Market by Country, 2018 - 2021, USD Million
  • TABLE 38 North America Research Institutes Market by Country, 2022 - 2028, USD Million
  • TABLE 39 North America Cancer Gene Therapy Market by Country, 2018 - 2021, USD Million
  • TABLE 40 North America Cancer Gene Therapy Market by Country, 2022 - 2028, USD Million
  • TABLE 41 US Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 42 US Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 43 US Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 44 US Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 45 US Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 46 US Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 47 Canada Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 48 Canada Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 49 Canada Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 50 Canada Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 51 Canada Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 52 Canada Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 53 Mexico Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 54 Mexico Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 55 Mexico Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 56 Mexico Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 57 Mexico Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 58 Mexico Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 59 Rest of North America Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 60 Rest of North America Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 61 Rest of North America Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 62 Rest of North America Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 63 Rest of North America Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 64 Rest of North America Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 65 Europe Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 66 Europe Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 67 Europe Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 68 Europe Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 69 Europe Gene Induced Immunotherapy Market by Country, 2018 - 2021, USD Million
  • TABLE 70 Europe Gene Induced Immunotherapy Market by Country, 2022 - 2028, USD Million
  • TABLE 71 Europe Oncolytic Virotherapy Market by Country, 2018 - 2021, USD Million
  • TABLE 72 Europe Oncolytic Virotherapy Market by Country, 2022 - 2028, USD Million
  • TABLE 73 Europe Gene Transfer Market by Country, 2018 - 2021, USD Million
  • TABLE 74 Europe Gene Transfer Market by Country, 2022 - 2028, USD Million
  • TABLE 75 Europe Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 76 Europe Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 77 Europe Hospitals Market by Country, 2018 - 2021, USD Million
  • TABLE 78 Europe Hospitals Market by Country, 2022 - 2028, USD Million
  • TABLE 79 Europe Diagnostic centers Market by Country, 2018 - 2021, USD Million
  • TABLE 80 Europe Diagnostic centers Market by Country, 2022 - 2028, USD Million
  • TABLE 81 Europe Research Institutes Market by Country, 2018 - 2021, USD Million
  • TABLE 82 Europe Research Institutes Market by Country, 2022 - 2028, USD Million
  • TABLE 83 Europe Cancer Gene Therapy Market by Country, 2018 - 2021, USD Million
  • TABLE 84 Europe Cancer Gene Therapy Market by Country, 2022 - 2028, USD Million
  • TABLE 85 Germany Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 86 Germany Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 87 Germany Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 88 Germany Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 89 Germany Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 90 Germany Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 91 UK Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 92 UK Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 93 UK Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 94 UK Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 95 UK Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 96 UK Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 97 France Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 98 France Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 99 France Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 100 France Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 101 France Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 102 France Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 103 Russia Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 104 Russia Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 105 Russia Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 106 Russia Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 107 Russia Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 108 Russia Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 109 Spain Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 110 Spain Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 111 Spain Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 112 Spain Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 113 Spain Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 114 Spain Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 115 Italy Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 116 Italy Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 117 Italy Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 118 Italy Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 119 Italy Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 120 Italy Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 121 Rest of Europe Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 122 Rest of Europe Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 123 Rest of Europe Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 124 Rest of Europe Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 125 Rest of Europe Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 126 Rest of Europe Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 127 Asia Pacific Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 128 Asia Pacific Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 129 Asia Pacific Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 130 Asia Pacific Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 131 Asia Pacific Gene Induced Immunotherapy Market by Country, 2018 - 2021, USD Million
  • TABLE 132 Asia Pacific Gene Induced Immunotherapy Market by Country, 2022 - 2028, USD Million
  • TABLE 133 Asia Pacific Oncolytic Virotherapy Market by Country, 2018 - 2021, USD Million
  • TABLE 134 Asia Pacific Oncolytic Virotherapy Market by Country, 2022 - 2028, USD Million
  • TABLE 135 Asia Pacific Gene Transfer Market by Country, 2018 - 2021, USD Million
  • TABLE 136 Asia Pacific Gene Transfer Market by Country, 2022 - 2028, USD Million
  • TABLE 137 Asia Pacific Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 138 Asia Pacific Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 139 Asia Pacific Hospitals Market by Country, 2018 - 2021, USD Million
  • TABLE 140 Asia Pacific Hospitals Market by Country, 2022 - 2028, USD Million
  • TABLE 141 Asia Pacific Diagnostic centers Market by Country, 2018 - 2021, USD Million
  • TABLE 142 Asia Pacific Diagnostic centers Market by Country, 2022 - 2028, USD Million
  • TABLE 143 Asia Pacific Research Institutes Market by Country, 2018 - 2021, USD Million
  • TABLE 144 Asia Pacific Research Institutes Market by Country, 2022 - 2028, USD Million
  • TABLE 145 Asia Pacific Cancer Gene Therapy Market by Country, 2018 - 2021, USD Million
  • TABLE 146 Asia Pacific Cancer Gene Therapy Market by Country, 2022 - 2028, USD Million
  • TABLE 147 China Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 148 China Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 149 China Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 150 China Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 151 China Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 152 China Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 153 Japan Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 154 Japan Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 155 Japan Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 156 Japan Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 157 Japan Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 158 Japan Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 159 India Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 160 India Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 161 India Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 162 India Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 163 India Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 164 India Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 165 South Korea Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 166 South Korea Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 167 South Korea Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 168 South Korea Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 169 South Korea Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 170 South Korea Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 171 Singapore Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 172 Singapore Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 173 Singapore Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 174 Singapore Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 175 Singapore Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 176 Singapore Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 177 Malaysia Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 178 Malaysia Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 179 Malaysia Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 180 Malaysia Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 181 Malaysia Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 182 Malaysia Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 183 Rest of Asia Pacific Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 184 Rest of Asia Pacific Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 185 Rest of Asia Pacific Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 186 Rest of Asia Pacific Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 187 Rest of Asia Pacific Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 188 Rest of Asia Pacific Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 189 LAMEA Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 190 LAMEA Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 191 LAMEA Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 192 LAMEA Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 193 LAMEA Gene Induced Immunotherapy Market by Country, 2018 - 2021, USD Million
  • TABLE 194 LAMEA Gene Induced Immunotherapy Market by Country, 2022 - 2028, USD Million
  • TABLE 195 LAMEA Oncolytic Virotherapy Market by Country, 2018 - 2021, USD Million
  • TABLE 196 LAMEA Oncolytic Virotherapy Market by Country, 2022 - 2028, USD Million
  • TABLE 197 LAMEA Gene Transfer Market by Country, 2018 - 2021, USD Million
  • TABLE 198 LAMEA Gene Transfer Market by Country, 2022 - 2028, USD Million
  • TABLE 199 LAMEA Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 200 LAMEA Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 201 LAMEA Hospitals Market by Country, 2018 - 2021, USD Million
  • TABLE 202 LAMEA Hospitals Market by Country, 2022 - 2028, USD Million
  • TABLE 203 LAMEA Diagnostic centers Market by Country, 2018 - 2021, USD Million
  • TABLE 204 LAMEA Diagnostic centers Market by Country, 2022 - 2028, USD Million
  • TABLE 205 LAMEA Research Institutes Market by Country, 2018 - 2021, USD Million
  • TABLE 206 LAMEA Research Institutes Market by Country, 2022 - 2028, USD Million
  • TABLE 207 LAMEA Cancer Gene Therapy Market by Country, 2018 - 2021, USD Million
  • TABLE 208 LAMEA Cancer Gene Therapy Market by Country, 2022 - 2028, USD Million
  • TABLE 209 Brazil Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 210 Brazil Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 211 Brazil Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 212 Brazil Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 213 Brazil Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 214 Brazil Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 215 Argentina Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 216 Argentina Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 217 Argentina Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 218 Argentina Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 219 Argentina Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 220 Argentina Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 221 UAE Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 222 UAE Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 223 UAE Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 224 UAE Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 225 UAE Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 226 UAE Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 227 Saudi Arabia Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 228 Saudi Arabia Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 229 Saudi Arabia Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 230 Saudi Arabia Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 231 Saudi Arabia Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 232 Saudi Arabia Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 233 South Africa Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 234 South Africa Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 235 South Africa Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 236 South Africa Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 237 South Africa Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 238 South Africa Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 239 Nigeria Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 240 Nigeria Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 241 Nigeria Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 242 Nigeria Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 243 Nigeria Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 244 Nigeria Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 245 Rest of LAMEA Cancer Gene Therapy Market, 2018 - 2021, USD Million
  • TABLE 246 Rest of LAMEA Cancer Gene Therapy Market, 2022 - 2028, USD Million
  • TABLE 247 Rest of LAMEA Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
  • TABLE 248 Rest of LAMEA Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
  • TABLE 249 Rest of LAMEA Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
  • TABLE 250 Rest of LAMEA Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
  • TABLE 251 Key Information - Novartis AG
  • TABLE 252 Key Information - GlaxoSmithKline PLC (GSK)
  • TABLE 253 Key Information - Amgen, Inc.
  • TABLE 254 Key Information - Bristol Myers Squibb Company
  • TABLE 255 key Information - Karyopharm Therapeutics, Inc.
  • TABLE 256 Key Information - Gilead Sciences, Inc.
  • TABLE 257 Key information - Adaptimmune Limited
  • TABLE 258 Key Information - Genelux Corporation
  • TABLE 259 key information - Sarepta Therapeutics, Inc.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Cancer Gene Therapy Market Size, By Therapy, 2018 - 2028, USD Million
  • FIG 3 Global Cancer Gene Therapy Market Share, By Therapy, 2021
  • FIG 4 Global Cancer Gene Therapy Market Share, By Therapy, 2028
  • FIG 5 Global Cancer Gene Therapy Market Size, By End User, 2018 - 2028, USD Million
  • FIG 6 Global Cancer Gene Therapy Market Share, By End User, 2021
  • FIG 7 Global Cancer Gene Therapy Market Share, By End User, 2028
  • FIG 8 Global Cancer Gene Therapy Market Size, By Region, 2018 - 2028, USD Million
  • FIG 9 Global Cancer Gene Therapy Market Share, By Region, 2021
  • FIG 10 Global Cancer Gene Therapy Market Share, By Region, 2028
  • FIG 11 Recent strategies and developments: Novartis AG
  • FIG 12 Recent strategies and developments: Bristol Myers Squibb Company